Overcoming Access Barriers and Practice Challenges to PCSK9 Inhibitor Implementation

Overcoming Access Barriers and Practice Challenges to PCSK9 Inhibitor Implementation

On-Demand Webcast
Faculty Presenter

Michael J. Bloch, MD, FACP, FASH, FSVM, FNLA
Associate Professor, Department of Internal Medicine
University of Nevada School of Medicine
Medical Director, Vascular Care
Renown Institute for Heart and Vascular Health
Reno, Nevada

Intended Learners

This activity is designed for cardiologists and cardiology-related healthcare professionals including residents, fellows, nurse practitioners, physician assistants, pharmacists, nurses and other healthcare professionals involved in the care of patients with hypercholesterolemia.

Learning Objectives
After completing this activity, participants should be able to:
  • Review the latest clinical trial evidence supporting the use of PCSK9 inhibitor therapies within the secondary prevention of CV events
  • Examine updates to guideline recommendations and expert consensus statements regarding the role of nonstatin therapies for the treatment of hypercholesterolemia and management of established CV disease
  • Identify specific patient populations that would benefit from LDL-cholesterol lowering utilizing PCSK9 inhibitor therapies
  • Develop strategies to overcome barriers that preclude access to PCSK9 inhibitors including prior authorizations, insurance denials and inconsistencies in the interpretation of prescription language
  • Translate the latest evidence, updates guidelines, and potential resolutions to access-related barriers to the individualized and targeted treatment of hypercholesterolemia and management of established CV disease
Activity Overview

This on-demand webcast is available with synchronized slides and video.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

Release date: June 26, 2018
Expiration date: June 26, 2019
Estimated time to complete: 1 hour

There is no fee associated with this activity.

Participants who completed the live version of this activity are not eligible to receive credit for this enduring material.

For questions regarding this educational activity, please call 609-371-1137.

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions towebmaster@naccme.com.


  In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.


This activity is approved for 1.0 contact hour (.1 CEU) of continuing pharmacy education (UAN: JA0006201-0000-18-077-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Peter Oettgen, MD, FACC, FAHA, FACP, Director of Preventive Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Nurse Planner: Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California


North American Center for Continuing Medical Education, LLC (NACCME), is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 15 continuing professional education units for completion of this activity/material.

CDR Accredited Provider #HM001 Level 3 Synthesis.

Planning Committee

The planning committee comprises Michael J. Bloch, MD, FACP, FASH, FSVM, FNLA, Peter Oettgen, MD, FACC, FAHA, FACP, Susie Seaman, NP; and Celeste Collazo, Jennifer Ilcyn, Mary Johnson, Mike Kearney, Todd Kunkler, Randy Robbin, Margaret Stefan and Susan Yarbrough, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Bloch: Research-AstraZeneca, Recor, Vascular Dynamics; Speaker's Bureau-Janssen, Amgen; Consultant-Amgen, Takeda International, Recor, Medtronic, Relypsa 

Ms. Seaman:
 Scientific advisor—Smith & Nephew, Inc.; Promotional Speakers’ Bureau—Smith & Nephew, Inc.

Dr. Oettgen has disclosed no relevant financial relationships with any commercial interest.

Dr. Collazo, Ms. Ilcyn, Ms. Johnson, Mr. Kearney, Mr. Kunkler, Mr. Robbin, Ms. Stefan, and Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that no off-label/unapproved drugs and/or devices will be discussed.

Grant Support

Supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.